Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Vas Narasimhan
Pharma
BMS, Merck, Amgen and more face near-term generic woes: Leerink
As patent expirations near for many of the world’s top drugmakers, companies will need to be diligent about M&A, according to a new Leerink report.
Fraiser Kansteiner
Nov 13, 2024 10:57am
Novartis CEO sees IRA impact ‘manageable’ in short run
Jul 18, 2024 11:05am
Novartis gears up for key expansions of 3 cancer drugs
Apr 23, 2024 3:37pm
Novartis reviews ties to China amid US biosecurity crackdown
Apr 23, 2024 11:07am
Big Pharma CEOs offer China renewed interest, policy advice
Mar 26, 2024 11:46am
PhRMA taps Gilead CEO Dan O'Day as its new board chair
Feb 21, 2024 2:51pm
